Cynata Therapeutics Limited 51S.F Stock
Cynata Therapeutics Limited Price Chart
Cynata Therapeutics Limited 51S.F Financial and Trading Overview
| Cynata Therapeutics Limited stock price | 0.15 EUR |
| Previous Close | 0.07 EUR |
| Open | 0.07 EUR |
| Bid | 0.07 EUR x 1296300 |
| Ask | 0.11 EUR x 1071500 |
| Day's Range | 0.07 - 0.07 EUR |
| 52 Week Range | 0.06 - 0.28 EUR |
| Volume | 5K EUR |
| Avg. Volume | 90 EUR |
| Market Cap | 16.51M EUR |
| Beta (5Y Monthly) | 0.768965 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.05 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
51S.F Valuation Measures
| Enterprise Value | -7098669 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.346995 |
| Price/Book (mrq) | 0.5112782 |
| Enterprise Value/Revenue | -2.73 |
| Enterprise Value/EBITDA | 0.722 |
Trading Information
Cynata Therapeutics Limited Stock Price History
| Beta (5Y Monthly) | 0.768965 |
| 52-Week Change | -71.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.28 EUR |
| 52 Week Low | 0.06 EUR |
| 50-Day Moving Average | 0.09 EUR |
| 200-Day Moving Average | 0.16 EUR |
51S.F Share Statistics
| Avg. Volume (3 month) | 90 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 179.63M |
| Float | 113.13M |
| Short Ratio | N/A |
| % Held by Insiders | 12.74% |
| % Held by Institutions | 21.47% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -388.74% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.24% |
| Return on Equity (ttm) | -40.44% |
Income Statement
| Revenue (ttm) | 2.6M EUR |
| Revenue Per Share (ttm) | 0.02 EUR |
| Quarterly Revenue Growth (yoy) | -74.20% |
| Gross Profit (ttm) | 7.77M EUR |
| EBITDA | -9829484 EUR |
| Net Income Avi to Common (ttm) | -9487002 EUR |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 16.41M EUR |
| Total Cash Per Share (mrq) | 0.12 EUR |
| Total Debt (mrq) | 0 EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 12.345 |
| Book Value Per Share (mrq) | 0.133 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -10252105 EUR |
| Levered Free Cash Flow (ttm) | -7206596 EUR |
Profile of Cynata Therapeutics Limited
| Country | Germany |
| State | VIC |
| City | Cremorne |
| Address | 100 Cubitt Street |
| ZIP | 3121 |
| Phone | 61 3 7067 6940 |
| Website | https://www.cynata.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Q&A For Cynata Therapeutics Limited Stock
What is a current 51S.F stock price?
Cynata Therapeutics Limited 51S.F stock price today per share is 0.15 EUR.
How to purchase Cynata Therapeutics Limited stock?
You can buy 51S.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cynata Therapeutics Limited?
The stock symbol or ticker of Cynata Therapeutics Limited is 51S.F.
Which industry does the Cynata Therapeutics Limited company belong to?
The Cynata Therapeutics Limited industry is Biotechnology.
How many shares does Cynata Therapeutics Limited have in circulation?
The max supply of Cynata Therapeutics Limited shares is 208.09M.
What is Cynata Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
Cynata Therapeutics Limited PE Ratio is now.
What was Cynata Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
Cynata Therapeutics Limited EPS is -0.05 EUR over the trailing 12 months.
Which sector does the Cynata Therapeutics Limited company belong to?
The Cynata Therapeutics Limited sector is Healthcare.